Oncology News

Compliance with hepatocellular carcinoma surveillance correlated with early diagnosis, better allocation of curative treatment and longer overall survival among patients with hepatitis C- or hepatitis B-associated compensated cirrhosis, according to a recently published study.

Stivarga therapy provided clinical benefit to patients with hepatocellular carcinoma and had similar adverse event rates regardless of the last Nexavar dose or time-to-progression on prior Nexavar therapy, according to a recently published study.

Metastatic cancer cells originating from colorectal cancer can reprogram their metabolism to create an enzyme that feeds on fructose in the liver, which increases proliferation, according to a recently published study.

Alcohol consumption correlated with significant changes to the oral microbiome that have been previously linked to alcohol-related diseases like periodontal disease, GI cancers, head and neck cancers and heart disease, according to new research published in the journal Microbiome.

PARIS — Alcohol abstinence did not reduce the risk for hepatocellular carcinoma among patients with Child-Pugh class A or B alcohol-related cirrhosis, according to a presentation at the International Liver Congress 2018.

PARIS — Treating hepatitis C virus in the early stage of disease saves money in drug and medical costs while lowering risk for decompensated cirrhosis, hepatocellular carcinoma, liver transplant and liver-related death, according to a presentation at the International Liver Congress 2018.

PARIS — Beginning Wednesday, April 11, Healio Gastroenterology and Liver Disease will provide live coverage from the International Liver Congress 2018.

Patients with hepatitis C have an increased risk for disease progression to cirrhosis and potentially hepatocellular carcinoma. Recent studies have focused on defining liver cancer risks related to HCV progression and the rates of liver cancer after HCV clearance with new direct-acting antivirals.

The gut microbiome has become a focused topic for researchers lately in hepatology and gastroenterology as its effects on gastric and liver health have yet to be fully understood. ecent studies have metabolites and phyla organizations that incrase the risk for certain liver diseases or may protect from conditions such as nonalcoholic fatty livr disease.

The phase 3 REACH-2 trial of ramucirumab met its primary endpoint of OS and its secondary endpoint of PFS for the second-line treatment of patients with hepatocellular carcinoma with high alpha-fetoprotein, according to the agent’s manufacturer.